

Journal of Hepatology

CTAT methods

Tables for a “Complete, Transparent, Accurate and Timely account” (CTAT) are now mandatory for all revised submissions. The aim is to enhance the reproducibility of methods.

- Only include the parts relevant to your study
- Refer to the CTAT in the main text as ‘Supplementary CTAT Table’
- Do not add subheadings
- Add as many rows as needed to include all information
- Only include one item per row

If the CTAT form is not relevant to your study, please outline the reasons why:

--

1.1 Antibodies

No antibodies were used in this study

1.2 Cell lines

Name	Citation	Supplier	Cat no.	Passage no.	Authentication test method
174xCEM.T2	Thierry S, <i>et al.</i> <i>Mol Cancer Ther</i> 2017,16:2817-27	ATCC	CRL-1992	5-10	GenePrint® 10 System (Promega, WI, USA)

1.3 Organisms

No organisms/animals were used in this study.

1.4 Sequence based reagents

Name	Sequence	Supplier
AE2a promoter	CpG sites –351, –348, –342, –329, –312, –310, –304, –299, –291, –286, –274, –272, –266, –260, –258, –254, –249, –246 bp relative to A in ATG start codon within exon 2 of AE2a transcript	Treated with EpiTect-Bisulphite Kit (QIAGEN, Hilden, Germany), and analysed by PyroMark™ Q96 pyrosequencer (QIAGEN, Hilden, Germany)
AE2b1 promoter	CpG sites –348, –330, –292, –279, –257, –255, –227 bp relative to A in ATG start codon within exon 1b1 of AE2b1 transcript	Treated with EpiTect-Bisulphite Kit (QIAGEN, Hilden, Germany), and analysed by PyroMark™ Q96 pyrosequencer (QIAGEN, Hilden, Germany).
AE2b2 promoter	CpG sites –447, –415, –351, –307, –296, –280, –263, –261, –244, –237, –228, –218, –205, –190, –172, –163, –111, –94 bp relative to A in ATG start codon within exon 1b2 of AE2b2 transcript	Treated with EpiTect-Bisulphite Kit (QIAGEN, Hilden, Germany), and analysed by PyroMark™ Q96 pyrosequencer (QIAGEN, Hilden, Germany).

1.5 Biological samples

Description	Source	Identifier
Liver biopses	Biobanks – Clinic University of Navarra (Pamplona, Spain) and Hospital Clinic (Barcelona, Spain)	Patient ID
PBMCs	Biobanks – Clinic University of Navarra (Pamplona, Spain) and Hospital Clinic (Barcelona, Spain)	Patient ID or anonymized ID from healthy blood-donors/volunteers

1.6 Deposited data

No data is deposited for this study

1.7 Software

Software name	Manufacturer	Version
PyroQ-CpG™	Biotage-QIAGEN (Hilden, Germany)	1.0.9
Genesis	Thallinger Lab, Graz University of Technology (graz, Austria)	1.8.1
GraphPad Prism 5	GraphPad Software (La Jolla, CA, USA)	5

1.8 Other (e.g. drugs, proteins, vectors etc.)

Name	Supplier	Cat No.
5-aza-2'-deoxycytidine	Sigma-Aldrich	A3656
Trichostatin A	Sigma-Aldrich	T1952

1.9 Please provide the details of the corresponding methods author for the manuscript:

Juan F. Medina, MD, PhD. Center for Applied Medical Research (CIMA) and School of Medicine, University of Navarra, Pamplona, Spain.

Email: jfmedina@unav.es

2.0 Please confirm for randomised controlled trials all versions of the clinical protocol are included in the submission. These will be published online as supplementary information.

No randomised controlled trials are included in this manuscript